Gastric Neoplasms
Oncology·MeSH: Stomach Neoplasms
Prevalence
3358.2 / 100K
Incidence
1547.2 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Tislelizumab | Jazz Pharmaceuticals plc (JAZZ) |
Frequently asked questions
How many drugs are in development for Gastric Neoplasms?
BioSniper tracks 1 drug in development for Gastric Neoplasms across 1 company.
How many clinical trials target Gastric Neoplasms?
There are 1 clinical trial targeting Gastric Neoplasms tracked by BioSniper.
What is the prevalence of Gastric Neoplasms?
The estimated prevalence of Gastric Neoplasms is approximately 3358.2 per 100,000 population.
Deep-dive into Gastric Neoplasms
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis